Large fat and skin necroses after deep subcutaneous injections of a slow-release somatostatin analogue in a woman with acromegaly

Growth Hormone and IGF Research

Volumn 20, Issue 6, 2010, Pages 438-440

  Burman, Pia ^a   Besjakov, Jan ^a   Svensjö, Tor ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Acromegaly; Adverse reaction; Fat necrosis; Lanreotide; Somatostatin analogue

Indexed keywords

ANGIOPEPTIN; GROWTH HORMONE;

ACROMEGALY; ADVERSE OUTCOME; AGED; ARTICLE; CASE REPORT; CONSERVATIVE TREATMENT; DRUG WITHDRAWAL; ERYTHEMA; FAT NECROSIS; FEMALE; GASTROINTESTINAL SYMPTOM; GROWTH HORMONE BLOOD LEVEL; HUMAN; INJECTION SITE PAIN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SKIN NECROSIS; SKIN SURGERY; SKIN ULCER; WOUND CLOSURE; WOUND CONTRACTION; WOUND DRESSING; WOUND HEALING;

ACROMEGALY; AGED, 80 AND OVER; DELAYED-ACTION PREPARATIONS; FAT NECROSIS; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; NECROSIS; PEPTIDES, CYCLIC; SKIN; SOMATOSTATIN;

EID: 78649633424     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2010.10.004     Document Type: Article

References (20)

1. Freda P.U. Somatostatin analogues in acromegaly. Clinical Review 150. J. Clin. Endocrinol. Metab. 2002, 87:3013-3018.
2. Bevan J.S., Atkinson Atkin S.L., AB Bouloux P.-M., Hanna F., Harris P.E., James R.A., McConell M., Roberts G.A., Scanlon M.F., Stewart P.M., Teasdale E., Turner H.E., Wass J.A.H., Wardlaw J.M. Primary medical therapy for acromegaly: an open, prospective, multi-center study of the effects of subcutaneous and intramuscular slow-release octreotide of growth hormone, insulin-like growth factor-I, and tumor size. J. Clin. Endocrinol. Metab. 2002, 87:4554-4563.
3. Karalis K., Mastorakos G., Chrousos G., Tolis G. Somatostatin analogues suppress the inflammatory reaction in vivo. J. Clin. Invest. 1994, 93:2000-2006.
4. Debono M., Hon L.-Q., Bax N., Blakeborough A., Newell-Price J. Gluteal nodules in patients with metastatic midgut carcinoid disease treated with depot somatostatin analogues. J. Clin. Endocrinol. Metab. 2008, 93:1860-1864.
5. Caron P., Cogne M., Raingeard I., Bex-Bachellerie V., Kuhn J.M. Effectiveness and tolerability of 3-year Lanreotide Autogel in patients with acromegaly. Clin. Endocrinol. 2006, 64:209-214.
6. Atmaca A., Erbas T. Lipoatrophy induced by subcutaneous administration of octreotide in the treatment of acromegaly. Exp. Clin. Endocrinol. Diab. 2005, 113:340-343.
7. Stewart P.M., Stewart S.E., Clark P.M., Sheppard M.C. Clinical and biochemical response following withdrawal of a long-acting depot injection form of octreotide (Sandostatin-LAR). Clin. Endocrinol. 1999, 50:295-299.
8. Garg A. Lipodystrophies. Am. J. Med. 2000, 108:143-155.
9. Dahl P.R., Zalla M.J., Winkelmann R.K. Localized involutional lipoatrophy: a clinicopathologic study of 16 patients. J. Am. Acad. Dermatol. 1996, 35:523-528.
10. Avilés-Izquierdo J.A., Longo-Imedio M.I., Hernánz-Hermosa J.M., Lázaro-Ochaita P. Bilateral localized lipoatrophy secondary to a single intramuscular corticosteroid injection. Dermatol. Online J. 2006, 12:17.
11. Vallés L., Gonzáles M., Polo I., Enguita A.B., Vanaclocha F., Ortiz-Romero P.L. Lipoatrophy associated with interferon alfa adjuvant therapy for melanoma. Arch. Dermatol. 2009, 145:98-99.
12. Rickardson T., Kerr D. Skin-related complications of insulin therapy: epidemiology and emerging management strategies. J. Am. Acad. Dermatol. 2003, 4:661-667.
13. Hartnett M.E., Martiniuk D.J., Saito Y., Geisen P., Peterson L.J., McColm J.R. Triamcinolone reduces neovascularization, capillary density and IGF-1 receptor phosphorylation in a model of oxygen-induced retinopathy. Invest. Ophthalmol. Vis. Sci. 2006, 47:4975-4982.
14. Soria A., Maubec E., Henry-Feugeas M.C., Marinho E., Le Bozec P., Huisse M.G., Pocidalo M.A., Descamps V., Crickx B. Panniculitis induced by interferon beta-1a vascular toxicity. Ann. Dermatol. Vénéréol. 2007, 134:374-377.
15. Grozinzky-Glasberg S., Shimon I., Korbonits M., Grossman A.B. Somatostatin analogues in the control of neuroendocrine tumours: efficacy and metabolism. Endocr. Relat. Cancer 2008, 15:701-720.
16. Danesi R., Agen C., Benelli U., Di Paolo A., Nardini D., Bocci G., Basolo F., Campagni A., Del Tacca M. Inhibition of experimental angiogenesis by the somatostatin analogue octreotide acetate (SMS 201-995). Clin. Cancer Res. 1997, 3:265-272.
17. Watson J.C., Balster D.A., Gebhardt B.M., O'Dorisio T.M., O'Dorisio M.S., Espenan G.D., Drouant G.J., Woltering E.A. Growing vascular endothelial cells express somatostatin subtype 2 receptors. Br. J. Cancer 2001, 85:266-272.
18. Adams R.L., Adams I.P., Lindow S.W., Zhong S.W., Atkin S.L. Somatostatin receptor 2 and 5 are preferentially expressed in proliferating endothelium. Br. J. Cancer 2005, 92:1493-1498.
19. Woltering E.A. Development of targeted somatostatin-based antiangiogenic therapy: a review and future perspective. Cancer Biother. Radiopharm. 2003, 18:601-609.
20. Seboek D., Linscheid P., Zulewski H., Langer I., Christ-Crain M., Keller U., Müller I. Somatostatin is expressed and secreted by human adipose tissue upon infection and inflammation. J. Clin. Endocrinol. Metab. 2004, 89:4833-4839.